2020
DOI: 10.1038/s41392-020-00383-5
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 5 publications
0
2
0
Order By: Relevance
“…28−30 However, the efficacy of PD-1 blockers is quite low (only 10−30%) due to the existence of multiple drug resistance mechanisms, and most patients cannot benefit from it. 31−34 As an important component of the tumor microenvironment (TME), M2-TAMs enhance tumor tolerance to anti-PD-1 therapy by overexpressing triggering receptor expressed on myeloid cells 2 (Trem2), 35,36 indoleamine 2,3-dioxygenase (IDO), and other molecules, 37−39 or by directly affecting the migration and infiltration of CD8 + T cells into tumors. 40−42 The repolarization of M2-TAMs is able to effectively enhance the efficacy of PD-1 blockers.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…28−30 However, the efficacy of PD-1 blockers is quite low (only 10−30%) due to the existence of multiple drug resistance mechanisms, and most patients cannot benefit from it. 31−34 As an important component of the tumor microenvironment (TME), M2-TAMs enhance tumor tolerance to anti-PD-1 therapy by overexpressing triggering receptor expressed on myeloid cells 2 (Trem2), 35,36 indoleamine 2,3-dioxygenase (IDO), and other molecules, 37−39 or by directly affecting the migration and infiltration of CD8 + T cells into tumors. 40−42 The repolarization of M2-TAMs is able to effectively enhance the efficacy of PD-1 blockers.…”
Section: Introductionmentioning
confidence: 99%
“…Immune checkpoint therapy aims to eliminate tumor cells by regulating the cytotoxic activity of T cells by co-suppression or co-stimulatory signals. Anti-PD-1 immunotherapy, whether used alone or in combination with other molecular targeted therapies as first-line or second-line treatment, is in a leading position in the treatment of many malignancies owing to its long-lasting, broad spectrum efficacy, low toxicity, and other advantages. However, the efficacy of PD-1 blockers is quite low (only 10–30%) due to the existence of multiple drug resistance mechanisms, and most patients cannot benefit from it. As an important component of the tumor microenvironment (TME), M2-TAMs enhance tumor tolerance to anti-PD-1 therapy by overexpressing triggering receptor expressed on myeloid cells 2 (Trem2), , indoleamine 2,3-dioxygenase (IDO), and other molecules, or by directly affecting the migration and infiltration of CD8 + T cells into tumors. The repolarization of M2-TAMs is able to effectively enhance the efficacy of PD-1 blockers. , …”
Section: Introductionmentioning
confidence: 99%